Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| NASDAQ | USD | Real-time | ||
| BATS Europe | SEK | Delayed | ||
| BATS Europe | GBP | Delayed | ||
| OTC Markets | USD | Delayed | ||
| Derived | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
(Reuters) - The UK drug regulator added an extremely rare nerve-damaging disorder, Guillain-Barré syndrome (GBS), as a very rare side effect of the AstraZeneca (NASDAQ:AZN)...
By Ankur Banerjee and Michael Erman (Reuters) - The U.S. Food and Drug Administration on Wednesday authorized booster doses of the COVID-19 vaccines from Moderna (NASDAQ:MRNA)...
BERLIN (Reuters) -Germany may miss its target to donate 100 million COVID-19 vaccine doses this year due to conditions imposed by manufacturers and delivery shortfalls, a health...
The stocks of the vaccine producers have gained a lot during 2021 due to the wide vaccination campaign around the world. Still, the COVID-19 pandemic is still not over as the virus...
It’s a pretty flat though mildly positive start to trade in Europe again after a decent handover from Asia, whilst Wall Street again registered fresh all-time highs. The S&P 500...
Following its successful IPO in May, Apontis Pharma's (DE:APPHG) maiden results highlight that the expansion of its single pill franchise continues at pace and should continue to...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 255.64 | 255.00 | 255.00 | -4.00 | -1.54% | 8.22K | London | |||
| 271.17 | 272.70 | 265.20 | +4.60 | +1.73% | 542.11K | London | |||
| 96.76 | 97.12 | 94.94 | +1.26 | +1.32% | 1.68M | London | |||
| 140.85 | 144.30 | 140.30 | -2.45 | -1.71% | 5.42M | London | |||
| 984.50 | 995.00 | 952.00 | -2.50 | -0.25% | 69.35K | London | |||
| 49.12 | 49.30 | 48.70 | +0.11 | +0.22% | 31.84M | London | |||
| 7,380.00 | 7,464.00 | 7,368.00 | -10.0 | -0.14% | 162.14K | London | |||
| 936.20 | 936.50 | 924.80 | +13.40 | +1.45% | 958.29K | London | |||
| 3,630.00 | 3,630.00 | 3,630.00 | +30.0 | +0.83% | 1.45K | London | |||
| 668.40 | 669.80 | 665.60 | -1.60 | -0.24% | 356.40K | London | |||
| 3,090.10 | 3,116.00 | 3,067.00 | +1.0 | +0.03% | 25.16K | London | |||
| 1,343.25 | 1,340.00 | 1,340.00 | -20.00 | -1.47% | 3.52K | London | |||
| 482.40 | 482.50 | 476.10 | 0.00 | 0.00% | 0.00 | London | |||
| 355.32 | 361.65 | 354.35 | -3.88 | -1.08% | 1.46M | London | |||
| 909.00 | 920.55 | 901.00 | +59.00 | +6.94% | 238.36K | London |
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.